The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
One more try for the link
https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202000585
https://chemistry-
europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202000585
* Extracts that don’t do justice * I would encourage all holders to give the paper a read :
“This suggests that not only are Affimers selecting a single conformation from the multiple dynamic possibilities in solution, but also that they could be used to select a conformation that is desired by the experimenter. In this case, not only does the Affimer bound conformation correspond to a small molecule bound conformation (thus this might conceptually be a better starting point for structure based drug design), but the groove closed conformation is also a conformation where the groove is too narrow to accommodate the BH3 helix, possibly potentiating the orthosteric competitive effect.”
“Similarly, BCL-2 binding Affimers themselves could be elaborated for therapeutic or diagnostic use;34, 70 goals we will pursue in due course. Of more generic significance is the observation that noncanonical folds can substitute for native folds in peptide/protein based inhibitors of PPIs;71, 72 this is reminiscent of the use of a ß-hairpin to mimic an a-helix for p53/hDM2 inhibition.73, 74 In contrast to those studies, the sequences identified here were obtained under selection pressure, and this poses the question: to date BCL-2 family proteins have only been observed to function in cells through the canonical a-helix/cleft motif; are there biological modulators of the BCL-2 family that act through other molecular modes of interaction yet to be discovered?“
GLA
Scroll down to 14
https://www.sharesmagazine.co.uk/awards/winners
Rally in Covid-Testing Stocks Here to Stay in Virus Resurgence
“The iShares U.S. Medical Devices ETF, known by its ticker IHI, peeled off a record Monday as testmakers and lab companies like Abbott Laboratories and Thermo Fisher Scientific Inc. were hit by a broader market decline. Despite the recent surge, some on Wall Street think investors still aren’t giving these firms proper credit for the billions of dollars in expected sales.”
Full article here:
https://www.bloomberg.com/news/articles/2020-10-20/rally-in-covid-testing-stocks-here-to-stay-in-virus-resurgence
Could anyone point me to the graph showing time span from exposure through infectious period and symptoms? I think perhaps AS used it in the recent presentation.
Family member works in a School and although now on half term reports are ensuing of quite a few cases.
I have to say despite my question I have absolute faith in avct and am simply awaiting a T/O which I see as inevitable, I just hope it’s not too soon and would be equally happy see the company grow with partnerships. avct represents about 80% of my pf.
Have not read one iota here in the last 24 hours of nonsense that would influence me otherwise.
GLA
Posted on this board by WengerOut just after the Stifel broadcast Tuesday 6 10 20 @14.32 pm:
“By dalep716
“So, at the Stifel Coporate Event Al answered my question relating to Clinical Validation of BAMS. The phrase he used was that "we have the samples and data so that Clinical Validation will completed in the immediate future". Perhaps I won't top slice again just now!”
GLA
Highly recommended, it’s a fascinating read...
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008364
GLA